ERBB2 and breast carcinoma: Numerous targeted radionuclide therapies have shown potential, including for example 177Lu-trastuzumab for HER2-positive breast cancer, and 90Y-FAPI-04 and 177Lu-FAPI-46 for advanced stage malignancies and metastatic breast cancer [119].